Page 16 - Bharat Biotech

Covid-19 vaccination sites drop to half in India amid shortage of doses

Number of locations down from 120,000 to 60,000 from April 3 to 7

Serum Institute, Bharat Biotech to speed up Covid-19 vaccine production

This comes after govt panel visits facilities of SII and Bharat Biotech

Govt's expert panel allows clinical trials for third dose of Covaxin

The expert panel of India's drug regulator, DCGI, has permitted Bharat Biotech to give a third dose of Covaxin to a few volunteers in its clinical trials of the Covid-19 vaccine, sources said

Brazil: Covaxin manufacturing facility fails to meet CGMP standards

Covaxin has demonstrated an interim vaccine efficacy of 81 per cent in the Phase 3 clinical trials

Supply chain threats

Vaccine nationalism shows how the pandemic has stressed trade

Bharat Biotech, CSIR collaborate to make raw material for vaccines

India now imports adjuvants and other chemicals for vaccine manufacturing

At $2.06 per dose, India pays the least for AstraZeneca Covid-19 vaccine

The price paid by different governments for a vaccine dose - including for the same vaccine - varies across countries, Unicef data shows

SII, Bharat Bio seek central fund injection to ramp up vaccine production

SII, Bharat Biotech want to increase production to meet domestic, foreign demand

Covaxin manufacturing may get a booster shot as demand for vaccines grows

Bharat Biotech also has another site at Bengaluru that is currently making vaccines other than Covaxin

Supply slipping, Centre to speed up Covid-19 vaccine delivery to states

Vaccine makers asked to send more doses to central government on priority

One year on

Ravages of last year's lockdown may still affect economy

Nepal gives emergency use approval to Bharat Biotech's Covid-19 vaccine

Nepal's national drug regulatory authority granted emergency use approval to Bharat Biotech's Covaxin, becoming the third country to approve India's indigenously developed Covid-19 vaccine

Vaccinating India: What next?

We must pull out all the stops to win the race against the virus. And trust each other to do the right thing

Clinically tried and tested: Bharat Biotech boss Ella wins Covaxin fight

Covaxin was India's first indigenously developed vaccine to be approved, controversially under "clinical trial mode" in the first week of January

Bharat Biotech's Covaxin gets authorisation for emergency use: V K Paul

So far 1.9 million people in the country have been given Covaxin, of whom 311 showed some side effects

Top headlines: Bharat Biotech's Covaxin off trial, IDBI Bank out of PCA

Saudi Aramco's $44-billion refinery project at Nanar in Ratnagiri has become a bone of contention between the Maharashtra government and the Centre

Covid-19 vaccine: Bharat Biotech's Covaxin goes off clinical trial mode

Expert panel recommends emergency use authorisation

Bharat Biotech's Covaxin safe, immunises for at least 3 months: Lancet

Probability of side effects from vaccine 10-12%, 6x lower than other shots

India's massive Covid vaccine campaign boosted by PM Modi receiving shot

Almost 21 million shots have been administered in India so far, up from 5.4 million a month ago

10 mn doses from India won't impact poor nations' vaccine access, says UK

UK Vaccine Deployment Minister Nadhim Zahawi has defended a shipment of 10 million doses of Covishield en route from India amid some concerns that it would impact supplies of poorer nations